Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Revvity announced a definitive agreement to acquire ACD/Labs, a scientific software provider used across pharmaceutical and materials science R&D. The deal is intended to broaden Revvity Signals’ research informatics portfolio by bringing together ACD/Labs’ tools for analytical characterization, molecular design, and process chemistry with Revvity’s existing discovery-to-manufacturing software. ACD/Labs’ offerings include the Spectrus platform for spectral analysis, Percepta for AI-driven property and ADMET prediction, Katalyst D2D for high‑throughput experimentation, Luminata for CMC decision support, and ADMS for analytical data management. Revvity says the combined stack will help scientists interpret complex data faster and connect discovery, development, scale-up, and quality workflows in a single SaaS environment. Closing is expected in late Q4 2025, subject to customary approvals. Company leaders framed the transaction as reinforcing the role of analytical sciences in accelerating innovation and creating a more unified data-to-insight experience for customers.